Kura Oncology reported a net loss of $49.5 million for the first quarter of 2024, compared to a net loss of $34.1 million for the same period in 2023. The company's cash, cash equivalents, and short-term investments totaled $527 million as of March 31, 2024, which is expected to fund operations into 2027.
Ziftomenib received Breakthrough Therapy Designation for NPM1-mutant AML.
Registration-directed trial of ziftomenib in NPM1-mutant AML is on track to complete enrollment by mid-2024.
Positive preliminary combination data reported for ziftomenib in NPM1-mutant and KMT2A-rearranged AML.
First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma.
Kura Oncology provided updates on expected milestones for their clinical trials, including completing enrollment for ziftomenib and identifying recommended doses for various combinations. They also plan to submit an IND application for ziftomenib in solid tumors and present data from the KURRENT-HN trial.
Analyze how earnings announcements historically affect stock price performance